James Price

15
Sep 2016
Share This
0 Comments

Canada’s stem cell community ready to innovate

Posted by

When it comes to innovation, Canada’s stem cell community is ready to roll.

That’s the message conveyed in an opinion piece in iPolitics, the must-read publication for those involved in — or merely fascinated by — Canadian politics.…

When it comes to innovation, Canada’s stem cell community is ready to roll.

That’s the message conveyed in an opinion piece in iPolitics, the must-read publication for those involved in — or merely fascinated by — Canadian politics.

The article responds to the call from Navdeep Bains, Canada’s Minister of Innovation, Science and Economic Development, for “fresh ideas and a joint action plan that will make innovation a national priority and put Canada on a firm path to long-term economic growth.”

The iPolitics piece points out that Canada’s stem cell community has “seen the writing on the wall, consulted, and forged a plan to act. It’s a blueprint designed to ensure our world-class talent grows here at home, that Canada reaps the economic rewards and that we remain a global leader in this sector. The Canadian Stem Cell Strategy has tremendous support across the country and is ready to be implemented.”

Three powerful voices united to co-author the article:

  • Peter MacKinnon, LLD, is President Emeritus of Athabasca University and former President and Vice-Chancellor of the University of Saskatchewan. His national appointments include the Prime Minister’s Advisory Committee on the Public Service and the Science, Technology and Innovation Council of Canada
  • Molly Shoichet, PhD,holds the Tier 1 Canada Research Chair in Tissue Engineering at the University of Toronto. She was the North American recipient of the L’Oréal-UNESCO Awards for Women in Science in 2015
  • James Price, MBA,is President & CEO of the Canadian Stem Cell Foundation.

“We wanted to make it clear that by making the Strategy a component of its Innovation Agenda, the Government will be putting stem cells to work for Canada’s future,” said Mr. Price.  “Not only will this set things in motion for many more people to be treated with new therapies, it will boost the economy and assure that thousands of new high-quality jobs will be created in this burgeoning industry.”

Click to read more Close
19
Nov 2015
Share This
0 Comments

Dr. Michael Rudnicki

Trudeau government urged to invest in stem cells

Posted by

A week after his lab unveiled its game-changing research into the root causes of Duchenne Muscular Dystrophy (read about it here), Dr.

A week after his lab unveiled its game-changing research into the root causes of Duchenne Muscular Dystrophy (read about it here), Dr. Michael Rudnicki is urging the new Trudeau government to “put its money where its future is: stem cell research.”

In an iPolitics piece published today, Dr. Rudnicki applauded the new government for appointing Dr. Kirsty Duncan as a full-standing minister of Science.

“This is a welcome development in a country that hasn’t been celebrated enough for its contributions to the global scientific research enterprise,” writes Dr. Rudnicki, Scientific Director and CEO of the Stem Cell Network (SCN).  “One area of research that is particularly underfunded in Canada is, ironically, one that can start making a drastic difference in the health of Canadians and people around the world: stem cell research and personalized medicine.”

He recommended the new government consider the Canadian Stem Cell Strategy, which he called “the most progressive results-orientated health care document produced in years.”  Crafted by a coalition of scientists, medical doctors, health charity executives, industry experts, business leaders and philanthropists, the Strategy is championed by the Canadian Stem Cell Foundation.

Thursday’s article is the second recent iPolitics piece advocating stronger investment in stem cell research and development. In August, Foundation President & CEO authored a piece titled Small cells, big future: Why we need a national stem cell effort.

Click to read more Close
03
Jun 2015
Share This
0 Comments

James Price, President & CEO of the Canadian Stem Cell Foundation, left, Sandra Henderson, Senior V-P of BMO Financial Group’s Eastern Ontario Division, and Tim Kluke, President & CEO of the Ottawa Hospital Foundation Credit: Erin McCracken, Ottawa South News

Investing in the future: BMO makes $1-million donation

Posted by

BMO’s  $1-million donation to support stem cell and regenerative medicine research in Canada is “an investment in the future,” says a senior executive with the leading financial institution.…

BMO’s  $1-million donation to support stem cell and regenerative medicine research in Canada is “an investment in the future,” says a senior executive with the leading financial institution.

“As the generations go on, it’s important for us to give back to the people we work with, we live with, who are in our communities,” Sandra Henderson, Senior Vice-President of BMO Financial Group’s Eastern Ontario Division, told Ottawa Community News.

The investment includes a $500,000 donation to the Ottawa Hospital’s Regenerative Medicine Program at the General campus’ Sinclair Centre, and $500,000 to the Canadian Stem Cell Foundation, of which $250,000 will go to the hospital’s new research initiatives and $250,000 to other national activities.

“By Canadian standards, that’s probably one of the largest corporate gifts specifically directed to stem cell research and regenerative medicine in the country,” James Price, Foundation’s President & CEO, told Ottawa Community News. “Canada is a leader in stem cell research, just as the Ottawa Hospital is.”

Currently, the Ottawa Hospital’s Regenerative Medicine Program has 250 scientists, research staff and trainees working at the Sinclair Centre for Regenerative Medicine and the Sprott Centre for Stem Cell Research.

The lab of Dr. Duncan Stewart, Executive Vice-President of Research at the Ottawa Hospital and Senior Scientist of the Ottawa Hospital Research Institute’s Regenerative Medicine Program, has been renamed the BMO Financial Group Laboratory in honour of the bank’s financial contribution.

 

Click to read more Close
23
Feb 2015
Share This
0 Comments

‘Let’s get this done’

Posted by

The Globe and Mail  today features an editorial pages article about the Canadian Stem Cell Strategy & Action Plan.

James Price, Foundation’s President and CEO, and Dr.

The Globe and Mail  today features an editorial pages article about the Canadian Stem Cell Strategy & Action Plan.

James Price, Foundation’s President and CEO, and Dr. Janet Rossant, Interim Director of the Ontario Institute for Regenerative Medicine and immediate past president of the International Society for Stem Cell Research, co-authored the article, headlined ‘Make Canada a magnet for stem cell trials’. Exploring the impact of experimental stem cell treatments abroad, the piece makes the case for Canada to build on its expertise in stem cell research and development to become the location of choice for high quality clinical trials.

“The real impact of many of the experimental stem cell treatments offered abroad is a question mark.” said the authors. “A better solution is made-in-Canada treatments. Give Canadians access to safe, cutting-edge and rigorously reviewed stem cell clinical trials here in Canada. Once fully proven, these treatments would be available across the country.” they added.

canada stem cells

Although several stem cell-related clinical trials are already under way in Canada (you can read about the recent announcement of a new stem cell trial for MS on our blog), there is the potential to do more.The Strategy & Action Plan will see Canada lead the way to bringing five to 10 new safe and proven therapies to the clinic within 10 years.

“Canadians should not need to travel abroad where experimental treatments are unproven and could carry serious health risks. We all want our loved ones to have access to the best care available when they need it. So let’s get this done.”

You can read the full version of the Globe and Mail article here.

Click to read more Close
19
Feb 2015
Share This
0 Comments

‘All we have to do is get it right’

Posted by

An article about the benefits of the Canadian Stem Cell Strategy & Action Plan is featured in the online version of Policy Options, Canada’s premier public policy journal.…

An article about the benefits of the Canadian Stem Cell Strategy & Action Plan is featured in the online version of Policy Options, Canada’s premier public policy journal.

Titled ‘How Canada can capitalize on its stem cell technology,’ the piece was written by Dr. Alan Bernstein, President and CEO of the Canadian Institute for Advanced Research and Chair of our Foundation’s Board of Directors, Dr. Allen Eaves, President and CEO of STEMCELL Technologies Inc., and James Price, our Foundation’s President and CEO. It illustrates how Canada can lead the way in stem cell science and translate research into five to 10 new therapies over the next 10 years.

“If we get it right, we can reduce human suffering from chronic, debilitating diseases, ease the burden on an overstressed health care system that is currently costing more than $200 billion a year, boost our economy by creating thousands of new high-skill jobs and own an area of advanced technology that was born in Canada.” said the authors.canada stem cells

“Canada’s role in all of this is vital. We have enormous scientific credibility, given that Canadians virtually founded the field: James Till and Ernest McCulloch proved the existence of stem cells more than 50 years ago at the Princess Margaret Hospital and went on to train and inspire subsequent generations of scientists who have positioned Canada at the leading edge.”

The print version of the article will be available soon in Policy Options, March-April 2015 edition.

Click to read more Close
Back to Top